Profiles in Pharma - July 1, 2017
Embracing diversity – for the sake of true innovation
Bahija Jallal’s curiosity and passion for science have been strong driving forces throughout her entire career, as has her belief in the need for diversity to truly bring forth innovation. A view that is also deeply incorporated in her job as Head of MedImmune. Editor’s note: In 2019 Bahika Jallal left MedImmune and became the […]
Clinical Trials - May 23, 2017
Results from AZ’s Phase III Zonda trial for benralizumab
Results from the Phase III ZONDA trial presented at the American Thoracic Society (ATS) 2017 International Congress demonstrated that adding benralizumab to standard of care allowed patients dependent on OCS to significantly reduce or discontinue steroids while maintaining asthma control. Detailed results of the ZONDA study were published online in the New England Journal of […]
Agreement - May 22, 2017
AstraZeneca in agreement with Recordati
AstraZeneca has entered into an agreement with Recordati for the commercial rights to Seloken/Seloken ZOK and associated Logimax fixed-dose combination treatments in Europe. Metoprolol succinate is a beta-blocker for the control of hypertension, angina and heart failure. Recordati will pay AstraZeneca $300 million upon completion of the agreement. AstraZeneca will also receive sales-related income through […]
Clinical Trials - May 15, 2017
AstraZeneca announces positive clinical trial results
AstraZeneca announces positive results for the Phase III PACIFIC trial. The trial is a randomised, double-blinded, placebo-controlled multi-centre trial of Imfinzi as sequential treatment in patients with locally-advanced, unresectable non-small cell lung cancer who had not progressed following standard platinum-based chemotherapy concurrent with radiation therapy. A planned interim analysis conducted by an Independent Data Monitoring […]
Collaboration - May 4, 2017
AstraZeneca, Pieris Pharmaceuticals collaborate
AstraZeneca announces a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals to develop novel inhaled drugs that leverage Pieris’ Anticalin platform. Under the collaboration, Pieris will be responsible for advancing its preclinical lead candidate, PRS-060 into Phase I clinical trials in 2017. PRS-060 is an Anticalin against interleukin-4 receptor alpha (IL-4Ra) with potential in asthma. […]
Pharma Business - April 26, 2017
AstraZeneca marks a key milestone
AstraZeneca has made a successful move to Cambridge, UK, with the ‘topping out’ of its new strategic R&D centre and global corporate headquarters at the heart of the Cambridge Biomedical Campus (CBC). The company, including its biologics research and development arm, MedImmune, already has 2 000 employees actively engaged in the city’s scientific, academic, clinical […]
